Yendamuri Sai, Malhotra Usha, Hennon Mark, Miller Austin, Groman Adrienne, Halloon Alaa, Reid Mary E
Department of Thoracic Surgery, Roswell Park Cancer Institute, Buffalo, New York, USA;; Department of Surgery, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, New York, USA.
Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA.
J Gastrointest Oncol. 2017 Feb;8(1):89-95. doi: 10.21037/jgo.2016.12.03.
Current published information of adenosquamous carcinoma (ASC) of the esophagus in the United States is limited to isolated case reports. We sought to study the clinical characteristics of this tumor using the Surveillance, Epidemiology and End Results (SEER) database.
Relevant data of all patients with esophageal cancer in the SEER database diagnosed from 1998-2010 was obtained. Demographic, grade, stage, treatment and survival characteristics of patients with ASC were summarized and compared to those patients with adenocarcinoma (ACA) and squamous cell carcinoma (SqCC). Univariate analyses across comparison groups were performed using Wilcoxon rank sum test for continuous covariates and the Pearson Chi-square test for categorical covariates. To evaluate the association of selected covariates to survival by histology, unadjusted and adjusted proportional hazards models were generated for the entire study population. To further control for the difference in covariates among the histology groups, propensity weighted Cox regression modeling was performed using the inverse propensity to treat weighting (IPTW) approach.
Of 29,890 patients with the histological subgroups, only 284 patients had ASC (1%). Patients with ACA had a higher grade (72.9% with grade III/IV) and presented with advanced stage (48.2% distant disease) than their comparison group. Patients with ASC had worse overall survival compared to ACA but not SqCC in both univariate and multivariate analyses (OR =0.76; P<0.05 and OR =0.86; P<0.05 respectively). These results were further confirmed by the propensity weighted Cox regression analysis. Analysis of the ASC population alone demonstrated that decreasing stage, radiation therapy (OR =0.59; P<0.001) and surgery (OR =0.86; P<0.001) were associated with better overall survival, but grade was not.
ASC of the esophagus is a rare histological variant comprising 1% of esophageal ACA in the Unites States. This histological subtype presents in later stages, at a higher grade and portends a poorer survival than the more common ACA. Radiation therapy and surgical resection of appropriate stage patients provide the best chance of survival.
目前美国已发表的食管腺鳞癌(ASC)相关信息仅限于个别病例报告。我们试图利用监测、流行病学和最终结果(SEER)数据库研究该肿瘤的临床特征。
获取SEER数据库中1998年至2010年诊断的所有食管癌患者的相关数据。总结ASC患者的人口统计学、分级、分期、治疗和生存特征,并与腺癌(ACA)和鳞状细胞癌(SqCC)患者进行比较。对连续协变量使用Wilcoxon秩和检验,对分类协变量使用Pearson卡方检验,对各比较组进行单因素分析。为评估所选协变量与组织学生存率的关联,为整个研究人群生成未调整和调整后的比例风险模型。为进一步控制组织学组间协变量的差异,采用逆倾向治疗加权(IPTW)方法进行倾向加权Cox回归建模。
在29890例组织学亚组患者中,仅有284例为ASC(1%)。ACA患者的分级更高(72.9%为III/IV级),且与比较组相比,呈现晚期(48.2%为远处疾病)。在单因素和多因素分析中,ASC患者的总生存期均比ACA患者差,但不比SqCC患者差(OR分别为0.76;P<0.05和OR为0.86;P<0.05)。倾向加权Cox回归分析进一步证实了这些结果。单独对ASC人群进行分析表明,分期降低、放疗(OR =0.59;P<0.001)和手术(OR =0.86;P<0.001)与更好的总生存期相关,但分级与之无关。
食管ASC是一种罕见的组织学变异类型,在美国占食管ACA的1%。这种组织学亚型出现于较晚阶段,分级较高,与更常见的ACA相比,预后较差。对合适分期的患者进行放疗和手术切除可提供最佳生存机会。